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Abstract
Background: Camptothecin (CPT) has recently attracted increasing attention as a promising anticancer agent for a 
variety of tumors. But the clinical application is largely hampered by its extreme water insolubility and unpredictable 
side effect. It is essential to establish an efficient and safe protocol for the administration of CPT versus melanoma.
Methods: Camptothecin was encapsulated with N-trimethyl chitosan (CPT-TMC) through microprecipitation and 
sonication. Its inhibition effect on B16-F10 cell proliferation and induction of apoptosis was evaluated by MTT assay 
and flow cytometric analysis in vitro. The anti-tumor activity of CPT-TMC was evaluated in C57BL/6 mice bearing B16-
F10 melanoma. Tumor volume, tumor weight and survival time were recorded. Assessment of apoptotic cells within 
tumor tissue was performed by TUNEL assay. Antiangiogenesis and antiproliferation effects of CPT-TMC in vivo were 
conducted via CD31 and PCNA immunohistochemistry, respectively.
Results: CPT-TMC efficiently inhibited B16-F10 cells proliferation and increased apoptosis in vitro. Experiment group 
showed significant inhibition compared with free CPT-treated group (81.3% vs. 56.9%) in the growth of B16-F10 
melanoma xenografts and prolonged the survival time of the treated mice (P < 0.05). Decreased cell proliferation, 
increased tumor apoptosis as well as a reduction in angiogenesis were observed.
Conclusions: Our data suggest that N-trimethyl chitosan-encapsulated camptothecin is superior to free CPT by 
overcoming its insolubility and finally raises the potential of its application in melanoma therapy.
Background
C a m p t o t h e c i n  ( C P T )  i s  a n  a l k a l o i d  i s o l a t e d  f r o m  t h e
stem of the tree Camptotheca acuminata with its chemi-
cal structure identified by Wall et al. in 1966 [1] for the
first time. It has a high anti-tumor activity in a wide range
of cancers, such as colon, ovarian, breast, melanoma,
lung and pancreatic cancers [2-6]. However, its poor
water solubility, low stability in physiological medium
and indefinite severe toxicity limite its further clinical
application. Therefore, finding a novel drug delivery sys-
tem is imperative to overcome these internal defects and
to increase the anticancer efficacy of CPT currently [7].
In recent years, chitosan, a natural biomateria 1
obtained by hydrolyzing chitin has been exerted more
and more emphasis in the fields of biomedical materials
for delaying the drugs release and favorable biological
properties including biocompatibility, biodegradability
and nontoxicity [8,9]. However, the fact that chitosan is
only soluble in an environment with pH values lower than
6.0 compromised its practical value in the pharmaceuti-
cal field. N-trimethyl chitosan (TMC), a derivate of chito-
san, solves this problem. Compared with chitosan, TMC
is soluble in the entire pH range. As a nonabsorbable and
nontoxic polymers, TMC have also been confirmed to
effectively ameliorate the permeation of hydrophilic mac-
romolecules across mucosal epithelia by opening the
intercellular tight junctions [10], thereby favoring the
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paracellular transport of drugs. In addition, this chitosan
derivation possesses excellent drug loading capability and
is a superior pharmaceutical excipients for drug delivery,
which might serve as an available drug carrier to encap-
sulate camptothecin and facilitate the uptake and reten-
tion of camptothecin in cancers.
Melanoma mostly originates in epidermal melanocytes.
It often occurs in the skin but could also be found in pig-
mented ocular structures, mainly in the uvea (choroid,
iris and ciliary body), the gastrointestinal tract, soft brain
(spinal) film, mouth and genital mucosa. The incidence of
malignant melanoma accounts for only 5% of all skin can-
cer, but is increasing year after year worldwide and causes
the largest number of skin cancer-related deaths world-
wide, 3 times of all the other skin cancers, accounting for
75% [11]. It is characterized by strong invasiveness, high
metastasis rate, rapid progression, and poor prognosis.
Currently the treatments for melanoma include surgery
resection, radiotherapy, chemotherapy, immunotherapy
a n d  b i o l o g i c a l  t h e r a p y ,  u s u a l l y  w i t h  s e v e r e  s i d e  e f f e c t s
[12]. Especially, some patients may develop relapse and
m etastasis  or eve n di e a ft e r treatment. Therefore, it is
urgently needed to develop a more reliable and less toxic
strategy to fight melanoma.
Previously, our laboratory encapsulated camptothecin
with N-trimethyl chitosan and tested its anti-tumor effi-
cacy in a mouse B16-F10 melanoma model. The present
study was aimed to verify whether the new protocol
could be more efficient and less toxic in melanoma treat-
ment.
Methods
Cell culture and reagents
B16-F10 mouse melanoma cell lines were purchased from
the American Type Culture Collection (ATCC, Rockville
MD, USA) and preserved by the State Key Laboratory of
Biotherapy of Human Diseases (West China Hospital of
Sichuan University, Chengdu, People's Republic of
China). Cells were cultured in RPMI1640 medium
(Gibico BRL, Grand Island, NY, USA) supplemented with
10% fetal bovine serum(FBS) plus 100 μg/ml amikacin in
a 37°C humidified chamber containing 5% CO2.
Preparation of camptothecine nanoparticle (CPT-TMC)
CPT-TMC was prepared by combination of microprecip-
itation and sonication as follows: Firstly, 6 mg/ml of
camptothecine was prepared by dissolving 30 mg camp-
tothecine into 5 ml dimethyl sulfoxide (DMSO) solution.
Then TMC was dissolved in water at the concentration of
5 mg/ml. Subsequently, 0.1 ml of camptothecine solution
was added dropwisely into 2 ml of TMC solution at 4°C.
The obtained colloid solution was ultrasonicated for 10
min also at 4°C. Finally, the colloid solution was dialyzed
against water using a membrane with a molecular weight
cutoff of 8,000-14,000 (Solarbio, China) for 3 days, then
the solution was centrifuged at 10,000 × g for 10 min to
remove insoluble CPT. The encapsulation rate of CPT to
TMC was about 10% in this paper. The prepared CPT
nanoparticles are well-dispersed and physical stable at 5
mg/ml TMC solution. The morphology of resulting CPT
nanoparticles was investigated by transmission electron
microscopy (TEM) observation. W e could find that the
needle-liked CPT nanoparticles were successfully pre-
pared. The chiastic size of nanoparticles was only about
30-50 nm and vertical size of nanoparticles was about 500
nm. The zeta potential of resulting CPT nanoparticles
was about +15 mv. CPT-TMC, CPT and TMC were dis-
solved in 0.9% NaCl solution (NS) for vitro and vivo stud-
ies.
Inhibition of proliferation in vitro
MTT assay was applied to investigate the inhibition effect
of CPT-TMC on B16-F10 cells proliferation. Medium
with CPT-TMC, CPT and TMC were prepared respec-
tively at same concentration. Each type of medium was
further diluted into a series of 1/2 dilutions in six tubes
(from 0.1 μg/ml to 3.2 μg/ml). Each dilution was added
into triplicate wells of B16-F10 cells seeded on 96-well
plates on the previous day (3 × 103 cells in complete
medium per well). The cells were incubated at 37°C in 5%
CO2 for 48 hours. Then, each well received 20 μl MTT
solution (5 mg/ml). After a 3-hour incubation, the
medium were removed and 150 μl DMSO were added.
We put the plate in a shaker before reading absorbance at
490 nm using a microplate reader (3550-UV, BIO-RAD,
USA) [13] after 20 min of incubation. The procedure was
repeated three times with similar results. The following
formula was used to calculate the inhibition rate of B16-
F10 cells proliferation: (1- experimental group OD value/
negative control OD value) ×100%. Media-only treated
(untreated) cells were considered as the negative control
group.
Apoptosis assay in vitro
Quantitative evaluation of cellular apoptosis was per-
formed by flow cytometric. Briefly, 2.5 × 105 B16-F10
cells were seeded in six-well plates and grew for 24 h to
70% confluence. Then cells were incubated with CPT-
T M C ,  C P T ,  T M C  a t  a  c o n c e n t r a t i o n  o f  0 . 4  μ g / m l ,  o r
media-only for another 48 h, respectively. After pro-
cessed as described above, the floated cells were dis-
carded while the attached cells were trypsinized and
thereafter washed twice with cold PBS. Then cells were
resuspended in prediluted binding buffer. Propidium
iodide (PI, 1 μg/ml) was added, and the mixtures were
immediately analyzed on an EPICS Elite ESP flow cytom-
eter (Beckman Coulter, Hialeah, Fla., USA).Liu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:76
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Animal model and study design
The studies involving mice were approved by the Institu-
tional Animal Care and Use Committee of Sichuan Uni-
versity (Chengdu, Sichuan, People's Republic of China).
Female C57BL/6 mice, 6 to 8 weeks old, nonfertile, were
purchased from the West China Experimental Animal
Center of Sichuan University (Sichuan, China), and were
maintained in pathogen-free conditions with sterile
chow. 1 × 105 B16-F10 melanoma cells resuspended in
0 . 0 5  m l  o f  P B S  w e r e  i n j e c t e d  s u b c u t a n e o u s l y  i n t o  t h e
right flank of each mouse. 9 days after injection when
most of the tumors were palpable, the tumor-bearing
mice were randomly divided into four groups (10/group):
(a) mice treated with CPT-TMC (2.5 mg/kg), (b) mice
treated with CPT (2.5 mg/kg), (c) mice treated with TMC
(25 mg/kg), and (d) mice treated with 0.9% NaCl solution
(NS,10 ml). Treatments were performed twice weekly for
2 weeks. Tumor sizes were measured every 3 days and
were calculated using the formula A × B2 × 0.52 (A,
length; B, width; all measured in millimeters) [14]. When
any mice began to moribund they were sacrificed. Subcu-
taneous tumors from sacrificed mice were removed and
fixed in 4% paraformaldehyde solution for immunochem-
istry staining.
Immunohistochemical assay
Tumors fixed in 4% paraformaldehyde solution were
embedded in paraffin and sliced into 5 μm sections for
tumor cell proliferation and microvessel density (MVD)
quantification with proliferating cell nuclear antigen
(PCNA) and CD31 immunohistochemistry respectively
by the method reported by Weidner et al [15]. PCNA spe-
cifically expressed in the proliferating cell nucleus and the
positive cells presented brown nuclei. PCNA immunos-
taining was used to assess tumor cell proliferation. CD31
had high affinity specific to vascular endothelial cell with
brown-staining by biotinylation under microscopy. CD31
vessel immunostaining was performed to assess the
angiogenesis in tumor tissues. Microvessel that presented
brown-staining endothelial cell or endothelial cell cluster
was considered as a countable microvessel.
The procedure was previously described in detail [16].
Sections were deparaffinized and rehydrated, followed by
antigen retrieval with retrieval buffer (10 mmol/l pH 6.0
EDTA citrate buffer; Dako, Glostrup, Denmark). The per-
oxidase activity was inhibited by 3% H2O2 and the sec-
tions were incubated with 10% normal goat serum to
blocking the non-specific binding of reagents. Rat anti-
mouse CD31 antibody (1:100, Santa Cruz Biotechnology)
and mouse anti-human PCNA antibody (1: 100, Santa
Cruz Biotechnology) were applied as primary antibody
overnight in a moist chamber at 4°C. Goat anti-rat immu-
noglobulin (1:100, Santa Cruz Biotechnology) and goat
anti-mouse immunoglobulin (1:100, Santa Cruz Biotech-
nology)were applied as secondary antibody for 40 min at
37°C, followed by the streptavidin-biotin complex
method. Immunostaining was developed using DAKO
Liquid DAB+ Substrate-Chromogen System (ZSJQ Bio-
technology, Beijing, China), followed by counterstaining
with hematoxylin.
Image of tumor tissue was taken by using OLYMPUS
BX600 microscope and SPOT FIEX camera.
TUNEL detection
Analysis of apoptotic cells in tumor tissue was performed
by Terminal deoxynucleotidyl transferase-mediated
dUTP nick-end labeling (TUNEL) staining using an
apoptotic cell detection kit following the manufacturer's
directions (Promega, Madison, Wisc., USA). TUNEL-
positive cells had pyknotic nucleus with dark green fluo-
rescent staining, pointed apoptosis. Images of the sec-
tions were taken by a fluorescence microscope (Olympus,
Tokyo, Japan). Apoptosis index was calculated by dividing
the number of TUNEL-positive cells by the total number
of cells in the field.
Evaluation of possible side effects
Mice, especially those treated with CPT-TMC, had been
observed for potential side effects through weight, appe-
tite, diarrhea, life span, and behavior until they were sac-
r i f i c e d .  O r g a n s  s u c h  a s  h e a r t ,  l i v e r ,  s p l e e n ,  l u n g ,  a n d
kidney were collected and made into 5 μm sections which
were stained with hematoxylin and eosin (H&E) and
observed under a microscope.
Statistical analysis
One-way analysis of variance (ANOVA) was used to
determine statistical significances in comparisons of
MTT assay, tumor volume, animal weight, tumor weight,
microvessel density (MVD), PCNA immunostaining and
TUNEL assay among different groups. Comparisons of
survival curves were based on the Kaplan-Meier method
and Log-rank test was used to compare survival rate. P <
0.05 was considered statistically significant.
Results
CPT-TMC inhibited cell proliferation and promoted 
apoptosis in vitro
B16-F10 cell proliferation was examined using the MTT
assay. As shown in Fig. 1, CPT-TMC and CPT signifi-
cantly reduced the proliferation of B16-F10 cells com-
pared with TMC and media-only (*P < 0.05). Their
inhibitory rate increased in a concentration-dependent
manner. However, no significant difference was observed
between CPT-TMC and CPT group, as well as TMC and
media-only group (P > 0.05).
Furthermore, it was evaluated by flow cytometry
whether the inhibition in cell proliferation resulted from
apoptosis induction. The numbers of apoptotic cells inLiu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:76
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CPT-TMC and CPT treated group were significantly
higher compared with other two groups. The apoptotic
rate showed 62% in CPT-TMC-treated group versus
57.1% in CPT-treated group, 10% in TMC-treated group
and 3.9% in media-only-treated group (Fig. 2). Results
obtained from flow cytometry strongly correlated with
the MTT assay data.
CPT-TMC inhibited tumor growth in vivo
Tumor volume in CPT-TMC-treated group was signifi-
cant smaller than control groups (P < 0.05). Mean tumor
volume (± SD) in CPT-TMC-treated mice was 1067 ± 311
mm3 versus 2108 ± 502 mm3 in CPT-treated mice, 3367 ±
353 mm3 in TMC-treated mice and 3607 ± 220 mm3 in
NS-treated mice (Fig. 3a). Although tumor volume in
TMC-treated group is smaller than NS-treated group,
there was no significant difference between them, P >
0.05. Tumor weight was measured on the third day after
the last treatment. Mean tumor weight was 0.324 ± 0.101
g, 0.748 ± 0.186 g, 1.616 ± 0.079 g and 1.736 ± 0.087 g in
CPT-TMC, CPT, TMC and NS treated group, respec-
tively (Fig. 3b).
CPT-TMC prolonged survival of tumor-bearing mice
Survival of CPT-TMC group was significantly prolonged
compared with controls, P < 0.05. As shown in Fig. 3c,
NS-treated group showed 0% survival on day 30, TMC-
treated group showed 0% survival on day 33, and CPT-
treated group showed 0% survival on day 42. In contrast,
CPT-TMC-treated group had a 50% survival rate persist-
ing up to day 42. The 0% survival of the CPT-TMC-
treated group happened on the day 51.
Toxicity observation
We measured the animal weight every 3 days and found
no significant difference among the four groups (Fig. 3d).
We also considered appetite, fur, behavior etc. for evalua-
tion of physical status and there were no changes in gross
measures. In addition, H&E histological staining of the
heart, liver, spleen, lung, and kidney indicated no signifi-
cant differences between CPT-TMC-treated and the con-
trol mice.
Figure 1 Inhibitory effect of CPT-TMC on B16-F10 cells proliferation in vitro. The proliferation of B16-F10 cells was assessed by the MTT assay. 
Data were assessed as percent cell viability in terms of media-only treated (non-treated) control cells at each drug concentration. It is clear that CPT-
TMC caused a dose-dependent inhibition of proliferation in vitro. Means ± SD (n = 3). *P < 0.05Liu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:76
http://www.jeccr.com/content/29/1/76
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CPT-TMC inhibited cell proliferation in vivo
Because CPT-TMC inhibited cell proliferation obviously
in vitro, we first examined its effects on tumor cell prolif-
eration by PCNA staining to explore the potential mecha-
nisms of CPT-TMC therapy in vivo. PCNA expression
was apparently reduced in CPT-TMC-treated group
compared with other groups (Fig. 4a). Our data showed
the percentage of PCNA-positive cells was 21.4 ± 4.3% in
CPT-TMC-treated tumors versus 47.4 ± 9.4% in CPT-
treated tumors, 78.8 ± 3.4% in TMC-treated tumors and
81.8 ± 3.1% in NS-treated tumors, respectively (Fig. 4b).
CPT-TMC increased intratumoral apoptosis
TUNEL assay was performed to detect tumor cell apop-
tosis to further investigate the role of CPT-TMC treat-
ment in tumor in vivo. As shown in Fig. 4c, CPT-TMC-
treated tumors showed significantly more apoptotic cells
(with green nuclei) than tumors from CPT, TMC or NS
treated groups. The apoptosis index was significantly
higher in CPT-TMC-treated group compared with the
controls (**P < 0.01): Mean apoptotic index ± SD of
tumor cells treated with CPT-TMC was 41.4 ± 2.8% when
it was 34 ± 3.9%, 8.2 ± 2.2%, or 5.8 ± 1.6% in CPT, TMC,
or NS treated group, respectively (Fig. 4d). These results
suggested that the increased tumor cell apoptosis by
CPT-TMC treatment in vivo may explain why tumor vol-
umes shrinked.
CPT-TMC inhibited intratumoral angiogenesis
Anti-angiogenesis is a major anticancer mechanism.
Therefore, MVD was evaluated in the tumors by counting
t h e  n u m b e r  o f  m i c r o v e s s e l s  i n  s e c t i o n s  s t a i n e d  w i t h
CD31 to further investigate the anti-angiogenic effect of
CPT-TMC. CD31-positive single or a cluster of cells were
counted as the microvessels (Fig. 4e). As shown in Fig. 4f,
MVD reduced the most significantly in CPT-TMC-
treated group (20.4 ± 2.9) compared with CPT (36.8 ±
2.5), TMC (58.8 ± 2.9) and NS treatments (61 ± 2; **P <
0.01). No significant difference was found between TMC
group and NS group (P > 0.05). The inhibition of tumor
neovascularization after CPT-TMC treatment may par-
tially explain the apoptosis induction which subsequently
reduce tumor progression and finally prolong survival
time.
Discussion
Nanoparticles may be defined as submicronic colloidal
systems that are generally composed of polymers. In
recent years, nanoparticles have been explored with some
success in maintaining or improving the anti-tumor
activity of the anticancer agents. Nanoparticles can pene-
trate into the membrane cells and spread along the nerve
synapses, blood vessels and lymphatic vessels, with the
capacity of selectively accumulating in different cells and
certain cell structures at the same time. The formulation
of nanoparticles and physicochemical parameters such as
pH, surface charge are critical for drug delivery. The
interaction of drug carrier systems with the biological
environment is important for designing strategies: these
systems should be independent in the environment and
selective at the pharmacological site. If designed appro-
priately, nanoparticles may act as a powerful drug vehicle
able to target tumor tissues or cells and prevent the drug
from inactivation during its transportation.
The selection of agents as drug delivery system is essen-
tial in the process of nanoparticle preparation for drug
Figure 2 Induction of apoptosis on B16-F10 cells by CPT-TMC in vitro. Cellular apoptosis was verified by flow cytometric analysis. B16-F10 Cells 
were treated with (a) media-only, (b) TMC, (c) CPT, or (d) CPT-TMC, respectively. It is clear that the number of apoptotic cells in CPT-TMC and CPT treat-
ed group was significantly higher compared with other two groups. The apoptotic rate showed 62% in CPT-TMC-treated group versus 57.1% in CPT-
treated group, 10% in TMC-treated group and 3.9% in media-only-treated group.Liu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:76
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delivery system. Chitosan is renowned for its function of
drug and gene delivery to cells and tissues [17,18]. The
medical materials made of chitosan, not only possess the
characteristics of the general physicochemical polymer
materials, such as mechanical stability and acceptability
to sterilization, but also can be transformed into small
molecular substances. Furthermore, they can also be eas-
ily absorbed by enzymatic hydrolysis, thereby with no
toxic effects in vivo. However, chitosan could only dis-
solve in acidic environments, compromising its applica-
tion prospect. N-trimethyl chitosan (TMC), a derivative
of chitosan with cation, is soluble within a wide pH range.
It can interact with the negative charge and tight junc-
tions on the cell surface, and afterwards open the tight
junctions between cells [19]. Due to its good biocompati-
bility, biodegradability, hydrophilicity and bio-adhesion,
TMC as a vascular targeting vector for anti-tumor che-
motherapy drugs, has superior to other synthetic vectors,
such as the toxic cationic lipid materials. Therefore, in
recent years, TMC has been widely used in drug targeting
delivery systems [20-22].
Camptothecin, a component of the stem of the tree
Camptotheca acuminata extracts, is known for its effi-
cient anti-tumor activity. It has multiple pharmacologic
actions including anti-angiogenesis, anti-tumor, immu-
nosuppression, anti-virus, and anti-early pregnancy. A
large number of studies have revealed that camptothecin
can induce apoptosis in leukemia, colon cancer, prostate
Figure 3 Anti-tumor efficacy of CPT-TMC in vivo. The tumor models were established in C57/BL6 mice (10/group) and then were treated with i.v. 
administration of 2.5 mg/kg CPT-TMC, 2.5 mg/kg free CPT, 25 mg/kg TMC, or NS twice per week, when tumors were palpable. (a) Tumor volume 
growth curve. Tumor sizes were measured every 3 days. CPT-TMC significantly inhibited tumor growth. There was a significant difference in tumor 
volume between CPT-TMC and control groups (P < 0.05). (b) Comparison of the tumor weight. At the third day after the last treatment, mice were 
sacrificed, and tumors were removed and weighed. Significant differences between CPT-TMC group and control groups are represented (*P < 0.05, 
**P < 0.01). Values are means ± SD. (c) Survival curve for tumor-bearing mice. A significant increase in survival in CPT-TMC-treated mice was also found 
when compared with the control groups (P < 0.05, by Log-rank test). And there was no statistical difference between TMC-treated mice and NS-treat-
ed mice (P > 0.05). (d) Lack of toxicity-dependent weight loss in tumor-bearing mice treated with CPT-TMC. There are no significant differences in 
weight among the four groups (P > 0.05). Values are means ± SD.Liu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:76
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cancer and other tumor cells. Despite the common clini-
cal use of camptothecin or its derivatives for the treat-
ment of cancers, its poor solubility still remains to be
resolved. In addition, because the lactone ring of camp-
tothecin and its derivatives is unstable in the presence of
human serum albumin, the active drug often easily
changes into inactive carboxylate form bound to albumin
[23]. The low stability of camptothecin hampers its deliv-
ery capability to the tumor to reach an effective concen-
tration. The selective increase in tumor tissue uptake of
anticancer agents would be of great interest.
Cengelli F, et al [24] covalently linked camptothecin to
biocompatible ultrasmall superparamagnetic iron oxide
nanoparticles (USPIOs) coated with polyvinylalcohol/
polyvinylamine (PVA/aminoPVA). These CPT-USPIO
conjugates exhibited antiproliferative activity in vitro
against human melanoma cells. Huang ZR, et al [25] pre-
pared lipid nanoparticles made of Precirol (solid lipid
nanoparticles; SLN-P), Compritol (SLN-C), Preci-
rol+squalene (nanostructured lipid carriers; NLC), and
squalene (a lipid emulsion; LE). No superiority for camp-
tothecin in cytotoxic activities in vitro was found except
for camptothecin loaded in the SLN-P. However, both of
the two researchers didn't use their camptothecin nano-
particles in vivo study. Loch-Neckel G, et al[26] evaluated
the effect of intraperitoneally administered methoxy
polyethylene glycol-(D,L-lactide) (PLA-PEG) (49 and 66.6
kDa) and Poly (D,L-lactide) PLA nanocapsules containing
CPT on lung metastatic spread in mice inoculated with
B16-F10 melanoma cells, and on the cytotoxic activity
against B16-F10 melanoma cells in vitro. In vitro study,
both PLA and 49 kDa PLA-PEG nanocapsules containing
CPT were more cytotoxic than the free CPT against B16-
F10 melanoma cells. Only CPT-loaded PLA-PEG 49 kD
nanocapsules significantly decreased the number of lung
metastases when compared with free drug.
Although there were some reports about encapsulating
camptothecin in nanoparticles as a potential antiprolifer-
ative treatment for cancer before, this study is the first
research that encapsulated camptothecin with N-trim-
ethyl chitosan by combination of microprecipitation and
sonication, and examined it in a mouse melanoma model.
Using this feasible model, we can investigate the local
tumor growth inhibition by CPT-TMC.
Figure 4 CD31, PCNA and TUNEL analyses for tumor tissue. (a) Tumor sections immunostained with an antibody against PCNA revealed that there 
were many strongly positive nuclei in control tumor tissues, whereas such nuclei were rare in tumor tissues of CPT-TMC-treated group. (b) Quantifi-
cation of PCNA staining showed percentage of PCNA-positive nuclei in CPT-TMC-treated group was the lowest among the four groups (*P < 0.05, **P 
< 0.01). (c) Apoptosis of tumor tissues in different groups were calculated by TUNEL assays, which showed that CPT-TMC induced a significant en-
hancement of apoptotic cells in contrast to control therapies. (d) Quantification of TUNEL assay shows that apoptosis index of CPT-TMC-treated tumor 
was much higher than that of control groups (*P < 0.05, **P < 0.01). (e) Tumor sections immunostained with anti-CD31 antibody (brown) for angio-
genesis assay. Representative sections were taken from tumor tissue of NS-treated, TMC-treated, CPT-treated and CPT-TMC-treated groups. (f) Histo-
morphometric assay for tumor microvessels revealed that MVD was significantly lower in CPT-TMC-treated group compared with the controls (*P < 
0.05, **P < 0.01).Liu et al. Journal of Experimental & Clinical Cancer Research 2010, 29:76
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Tumor blood vessels apt to expand compared with
physiological vessels. The rapidly expanding tumor vas-
culature often has a discontinuous endothelium, with
gaps between the cells that may be several hundred nano-
meters large [27,28]. We encapsulated camptothecin with
N-trimethyl chitosan, and the nanoparticles may be tar-
geted to the particulate region of capillary endothelium.
Nanoparticles loaded with anticancer agents can success-
fully increase drug concentration in cancer tissues and
decrease drug concentration in other normal tissues, and
then enhance anti-tumor efficacy and improve the safety
of CPT. N-trimethyl chitosan can provide controlled and
targeted delivery of camptothecin with better efficacy.
The effect of CPT-TMC on B16-F10 cells was explored
in vitro. Results showed that both CPT-TMC and CPT
significantly inhibited B16-F10 cells proliferation and
induced apoptosis while TMC showed no similar effect.
No significant difference was found in the MTT assay
between CPT and CPT-TMC. The possible reason for the
lack of difference is that the pharmacologically important
lactone ring of camptothecin is unstable in the presence
of serum albumin which results in the conversion of the
active drug to the inactive carboxylate form bound to
albumin while there is no serum albumin in vitro to do so.
In an attempt to overcome the disadvantage we encapsu-
lated camptothecin with N-trimethyl chitosan and the
results showed that camptothecin nanoparticle is superi-
ority in vivo rather than in vitro.
We applied the CPT-TMC on a mouse melanoma
model. As expected, CPT-TMC efficiently inhibited the
growth of B16-F10 cancer xenografts, and significantly
prolonged the survival time of the treated mice, while
CPT only partially inhibited tumor growth. It may be
explained that there was a temporary high serum but low
intratumor levels of CPT because of nonselective expres-
sion and subsequent elimination. CPT-TMC showed sig-
n i f i c a n t  s u p p r e s s i o n  o f  t u m o r  g r o w t h  w i t h  t h e  d r u g
administered in the dose and schedule under the condi-
tions of our study, causing no gross toxicity of the ani-
mals. In contrast, there was no significant difference in
tumor volume and survival time between TMC-treated
and NS-treated mice. Hence, CPT-TMC is a more tumor-
specific approach, enhancing the therapeutic efficacy on
tumor.
To elucidate the anti-tumor mechanism of CPT-TMC
in vivo, proliferation, apoptosis and angiogenesis were
systematically analyzed. Immunohistochemistry staining
with PCNA and TUNEL assay of tumor tissue were per-
formed. Our findings were consistent with the anti-pro-
liferation and apoptosis-inducing ability of camptothecin
mentioned above. The quantitative analysis showed that
CPT-TMC-treated group had a significant reduction of
PCNA-positive cells and increment of apoptotic index in
contrast to other groups. Accumulated evidence indicates
that a nascent tumor can stimulate angiogenesis. Angio-
genesis plays a vital role in tumor growth. When a tumor
grows to 1-2 mm, tumor cells have to depend on newborn
vessels to provide oxygen and nutrients [29]. Hence, anti-
angiogenic therapy has been considered to be a new
direction to fight cancers [30-34]. When angiogenesis is
inhibited, the supported tumor cells by those vessels sub-
sequently suffer apoptosis [35]. Treatment with CPT-
TMC resulted in apparent reduction in intratumoral
MVD of melanoma compared with controls.
In summary, we demonstrated that CPT-TMC exerted
anti-tumor activity through inhibiting cells proliferation,
increasing apoptosis and reducing MVD. It may suggest
that CPT-TMC was more effective than single CPT treat-
ment. No significant difference in the percentage of
PCNA- and TUNEL-positive cells, as well as MVD was
found between the TMC and NS groups, suggesting that
the control vector only posed minor impact on the anti-
tumor effects and little toxicity to cells in vivo. These
results strongly demonstrated that CPT-TMC may be an
efficient and safe protocol for the administration of CPT
versus melanoma.
Conclusions
In conclusion, being encapsulated with N-trimethyl chi-
tosan made camptothecin more efficacious against
mouse melanoma cancer. Given its anti-tumor effect,
there is a real hope that N-trimethyl chitosan-encapsu-
lated camptothecin could serve as a novel and safe thera-
peutic option in the treatment of human melanoma.
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